Barman Ruby, Sarma Adity, Ahmed Zarika, Dutta Anupam
Department of Pathology, Assam Medical College and Hospital, Dibrugarh, IND.
Department of General Medicine, Assam Medical College and Hospital, Dibrugarh, IND.
Cureus. 2025 Apr 16;17(4):e82365. doi: 10.7759/cureus.82365. eCollection 2025 Apr.
Hemophilia A is an X-linked bleeding disorder caused by mutations in the F8 gene, with intron 22 inversion being the most common genetic alteration in severe cases. This study aimed to determine the prevalence of intron 22 inversion in hemophilia A patients in Assam, Northeast India, and evaluate its correlation with disease severity.
This hospital-based observational study included 80 hemophilia A patients at Assam Medical College from March 2023 to February 2024. Clinical history, coagulation tests (activated partial thromboplastin time (APTT), prothrombin time (PT), and factor VIII assay), and nested long-distance polymerase chain reaction (NLD-PCR) for intron 22 inversion detection were performed. Statistical analysis was conducted using SPSS v25 (IBM Corp., Armonk, New York, USA).
Among the 80 patients, 41 (51.25%) had severe hemophilia A, 22 (27.5%) moderate, and 17 (21.25%) mild. Intron 22 inversion was detected in 24 patients (30%), with a significantly higher prevalence in severe cases 22/41 (53.65%) compared to moderate 2/22 (9.09%) and mild cases (0%) (p < 0.001). APTT was significantly prolonged in severe cases (109.35 ± 15.62 sec) compared to moderate (86.92 ± 9.87 sec) and mild cases (61.71 ± 8.94 sec) (p < 0.001), reinforcing the genetic basis of disease severity.
This study confirms a strong correlation between intron 22 inversion and severe hemophilia A, consistent with global and Indian studies. It emphasizes the need for routine genetic screening for early diagnosis and personalized treatment strategies, including genetic counseling. Future research should explore other F8 mutations, gene therapy, and the role of intron 22 inversion in inhibitor development.
甲型血友病是一种由F8基因突变引起的X连锁出血性疾病,内含子22倒位是严重病例中最常见的基因改变。本研究旨在确定印度东北部阿萨姆邦甲型血友病患者内含子22倒位的患病率,并评估其与疾病严重程度的相关性。
这项基于医院的观察性研究纳入了2023年3月至2024年2月在阿萨姆医学院的80例甲型血友病患者。进行了临床病史、凝血试验(活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)和因子VIII测定)以及用于检测内含子22倒位的巢式长距离聚合酶链反应(NLD-PCR)。使用SPSS v25(美国纽约州阿蒙克市IBM公司)进行统计分析。
80例患者中,41例(51.25%)患有严重甲型血友病,22例(27.5%)为中度,17例(21.25%)为轻度。24例患者(30%)检测到内含子22倒位,严重病例中的患病率显著高于中度(2/22,9.09%)和轻度病例(0%)(22/41,53.65%)(p < 0.001)。与中度(86.92 ± 9.87秒)和轻度病例(61.71 ± 8.94秒)相比,严重病例的APTT显著延长(109.35 ± 15.62秒)(p < 0.001),强化了疾病严重程度的遗传基础。
本研究证实内含子22倒位与严重甲型血友病之间存在密切相关性,这与全球和印度的研究一致。它强调了进行常规基因筛查以实现早期诊断和制定个性化治疗策略(包括遗传咨询)的必要性。未来的研究应探索其他F8突变、基因治疗以及内含子22倒位在抑制剂形成中的作用。